FDA inspection
Raybow (Suzhou) Pharmaceutical Co., Ltd.: FDA inspection ending Oct 18, 2018
FDA inspection 1071681 · No Action Indicated (NAI) · Suzhou
Key facts
| Inspection ID | 1071681 |
|---|---|
| Firm | Raybow (Suzhou) Pharmaceutical Co., Ltd. |
| FEI number | 3007114474 |
| Address | Bixi Subdistrict 18, Tonglian Road; Changshu |
| City | Suzhou |
| Country | China |
| Fiscal year | 2019 |
| Inspection end date | Oct 18, 2018 |
| Classification | No Action Indicated (NAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- No Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data